CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of t...
Phase 2
Commack, New York, United States and 7 other locations
This study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in pe...
Phase 2
Commack, New York, United States and 7 other locations
together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Esca...
Phase 1
Stony Brook, New York, United States and 27 other locations
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic...
Phase 2
Stamford, Connecticut, United States and 3 other locations
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia...
Phase 2
New Haven, Connecticut, United States and 7 other locations
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...
Phase 3
Shirley, New York, United States and 83 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 3
New Haven, Connecticut, United States and 11 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Norwich, Connecticut, United States and 179 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Stony Brook, New York, United States and 79 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Stamford, Connecticut, United States and 216 other locations
Clinical trials
Research sites
Resources
Legal